相关期刊:《Journal of Clinical and Translational Hepatology》《Current Medical Science》《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》《World Journal of Gastroenterology》更多>>
Supported by National Research Foundation of Korea,NO.2022R1I1A1A0106363612;Korea Health Industry Development Institute,No.HI23C1489.
BACKGROUND Clinical factors predicting graft survival(GS)after ABO-incompatible(ABOi)liver transplantation(LT),and differences between recipients with and without hepatocellular carcinoma(HCC)are unclear.AIM To analyz...
This research was partially supported by National Natural Science Funds for Distinguished Young Scholar of China,(No.81625003);Key Program,National Natural Science Foundation of China,(No.81930016,No.81570589,No.81702858);Youth Program of National Natural Science Foundation of Zhejiang Province(No.LQ17H160006);National S&T Major Project(No.2017ZX10203205).
Background and Aims:Liver transplantation(LT)using ABO-incompatible(ABOi)grafts can extend the donor pool to a certain extent and hence reduce the waiting time for transplantation.However,concerns of the impending pro...
Objective:Patients undergoing hematopoietic stem cell transplant(HSCT)need frequent transfusions,until their red blood cells(RBCs)and platelets start to recover.The safe transfusion for patients who receive ABO-incomp...
Supported by The Third People's Hospital of Shenzhen Scientific Research Project,No.G2021008 and No.G2022008;Shenzhen Key Medical Discipline Construction Fund,No.SZXK079;Shenzhen Science and Technology Research and Development Fund,No.JCYJ20210324131809027 and No.JCYJ20220530163011026.
BACKGROUND Human immunodeficiency virus(HIV)-positive patients coinfected with hepatitis B virus(HBV)are eligible for liver transplantation(LT)in Africa and Southeast Asia,particularly China.However,the outcome of HIV...
the National Nat-ural Science Foundation of China(81625003,81800578,and 81930016);Key Research&Development Plan of Zhejiang Province(2019C03050 and 2021C03118);Projects of Medical and Health Technology Program in Zhejiang Province(WKJ-ZJ-2120).
Background:The shortage of donor liver restricts liver transplantation(LT).Nowadays,donor liver with ABO blood group incompatibility between donor and recipient has become an option to expand the source of donor liver...
By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done succes...
National Natural Science Foundation of China(Nos.81870513,81600584);the Sichuan Science and Technology Program(No.2019YJ0133);the Chengdu Science and Technology Program(No.2019-YF05-00084-SN);1.3.5 Project for Disciplines of Excellence Clinical Research Incubation Project,West China Hospital,Sichuan University(Nos.2018HXFH049,ZY2016104,2021HXFH007)。
Background:Although ABO-incompatible(ABOi)kidney transplantation(KT)has been performed successfully,a standard preconditioning regimen has not been established.Based on the initial antidonor ABO antibody titers,an ind...
BACKGROUND Liver transplantation(LT)has become an acceptable curative method for children with several liver diseases,especially irreversible acute liver failure and chronic liver diseases.King Chulalongkorn Memorial ...
This study was supported by a grant from the Ministry of Health and Welfare(No.HI18C0532),Republic of Korea;
ABO blood group-incompatible(ABOi)transplantation has been developed to overcome the serious problem of donor organ shortage.However,antibody-mediated rejection(ABMR)remains as the main limitation to successful ABOi t...
supported by the National Natural Science Foundation of China (No. 81670148);the Health Science and Technology Project of Zhejiang Province (No. 2012KYB079), China。
Pure red cell aplasia(PRCA) is a well-recognized complication of ABO major mismatched allogeneic hematopoietic stem cell transplantation(allo-HSCT), with a reported incidence of 10% – 20%(Zhidong et al., 2012;Busca e...